AKUMS launches Aztreonam-Avibactam injection to combat multidrug-resistant infections
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Subscribe To Our Newsletter & Stay Updated